HeartBeam (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses, with the transaction completed on April 16, 2026. The offering, supported by key stakeholders including ClearCardio, company leadership and institutional investors, will fund commercialization of HeartBeam's FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection technologies, expansion of AI capabilities and general corporate purposes.
This capital infusion is critical for HeartBeam as it transitions from a development-stage company to a commercial entity. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The platform is designed to collect ECG signals in 3D from three non-coplanar directions and synthesize them into a standard 12-lead ECG, enabling portable devices that can be used outside of medical facilities.
The funding will accelerate the rollout of HeartBeam's cable-free device, which aims to deliver actionable heart intelligence to physicians for identifying cardiac health trends and acute conditions. The company holds over 20 issued patents related to its technology. For more details, the full press release is available at https://ibn.fm/9iNYY.
The offering's success, with participation from existing stakeholders and institutional investors, signals confidence in HeartBeam's technology and market potential. The company plans to use the proceeds to expand its AI capabilities, which could enhance diagnostic accuracy and patient monitoring. HeartBeam's extended-wear patch technology, also in development, aims to provide continuous cardiac monitoring for extended periods, addressing a key need in remote patient management.
HeartBeam's technology is particularly significant given the rising prevalence of cardiovascular diseases and the need for accessible diagnostic tools. By enabling 12-lead ECG synthesis from a portable, cable-free device, the company could reduce barriers to timely cardiac assessment, potentially improving outcomes for patients with arrhythmias or heart attacks. The company's forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, involve risks and uncertainties, including those detailed in its SEC filings. Investors can find the latest news and updates at https://ibn.fm/BEAT.
With the closing of this offering, HeartBeam is positioned to advance its commercial strategy and bring its innovative cardiac monitoring solutions to market. The company's focus on synthesizing 12-lead ECGs from a compact device represents a potential shift in how cardiac care is delivered, moving from hospital-based testing to patient-centric, remote monitoring. The success of this offering and subsequent commercialization efforts will be closely watched by investors and healthcare providers alike.
